| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Clelia Tiziana Storlazzi, Fredrik Vult Von Steyern, Henryk A Domanski, Nils Mandahl, Fredrik Merten. Biallelic somatic inactivation of the NF1 gene through chromosomal translocations in a sporadic neurofibroma. International journal of cancer. vol 117. issue 6. 2005-12-14. PMID:15986446. |
inactivation of both copies of nf1 has been described in a few neurofibromas from nf1 patients, and loh at the same locus has been reported in additional cases. |
2005-12-14 |
2023-08-12 |
Not clear |
| Clelia Tiziana Storlazzi, Fredrik Vult Von Steyern, Henryk A Domanski, Nils Mandahl, Fredrik Merten. Biallelic somatic inactivation of the NF1 gene through chromosomal translocations in a sporadic neurofibroma. International journal of cancer. vol 117. issue 6. 2005-12-14. PMID:15986446. |
to the best of our knowledge, this represents the first demonstration of a somatic biallelic inactivation of the nf1 gene in neurofibroma, providing further evidence for the importance of nf1 inactivation also in sporadic neurofibromas. |
2005-12-14 |
2023-08-12 |
Not clear |
| Marge Lammert, Victor-Felix Mautner, Lan Kluw. Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients. BMC cancer. vol 5. 2005-10-17. PMID:15703081. |
neurofibromas are benign tumors of the peripheral nerves and hallmark of neurofibromatosis type 1 (nf1), a tumor suppressor gene syndrome. |
2005-10-17 |
2023-08-12 |
Not clear |
| Marge Lammert, Victor-Felix Mautner, Lan Kluw. Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients. BMC cancer. vol 5. 2005-10-17. PMID:15703081. |
many female nf1 patients are thus concerned about the possibility that hormonal contraceptives may stimulate the growth of their neurofibromas. |
2005-10-17 |
2023-08-12 |
Not clear |
| Biplab Dasgupta, Yijun Yi, David Y Chen, Jason D Weber, David H Gutman. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer research. vol 65. issue 7. 2005-05-26. PMID:15805275. |
individuals with the tumor predisposition syndrome, neurofibromatosis 1 (nf1), are prone to development of nervous system tumors, including neurofibromas and pilocytic astrocytomas. |
2005-05-26 |
2023-08-12 |
mouse |
| George A Mashour, Stephanie N Drissel, Silke Frahm, Faris Farassati, Robert L Martuza, Victor-F Mautner, Andrea Kindler-Röhrborn, Andreas Kurt. Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids. Oncogene. vol 24. issue 14. 2005-04-18. PMID:15735744. |
neurofibromatosis type 1 (nf1) is a common genetic disorder of the nervous system resulting in neurofibromas and malignant peripheral nerve sheath tumors (mpnst). |
2005-04-18 |
2023-08-12 |
human |
| Lauren Fishbein, Bonnie Eady, Nicholas Sanek, David Muir, Margaret R Wallac. Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. Cancer genetics and cytogenetics. vol 157. issue 2. 2005-04-13. PMID:15721644. |
neurofibromatosis 1 (nf1) is an autosomal dominant disorder with the characteristic feature being the neurofibroma. |
2005-04-13 |
2023-08-12 |
Not clear |
| Lauren Fishbein, Bonnie Eady, Nicholas Sanek, David Muir, Margaret R Wallac. Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. Cancer genetics and cytogenetics. vol 157. issue 2. 2005-04-13. PMID:15721644. |
we analyzed the methylation state of the nf1 promoter in normal schwann cells (the cell type clonally expanded in neurofibromas) and in nf1-related plexiform tumor samples with unidentified somatic mutations. |
2005-04-13 |
2023-08-12 |
Not clear |
| Sofie De Schepper, Joachim Boucneau, Jo Lambert, Ludwine Messiaen, Jean-Marie Naeyaer. Pigment cell-related manifestations in neurofibromatosis type 1: an overview. Pigment cell research. vol 18. issue 1. 2005-03-30. PMID:15649148. |
the most commonly seen tumors in nf1 patients are the (sub)cutaneous neurofibromas. |
2005-03-30 |
2023-08-12 |
Not clear |
| Sofie De Schepper, Joachim Boucneau, Jo Lambert, Ludwine Messiaen, Jean-Marie Naeyaer. Pigment cell-related manifestations in neurofibromatosis type 1: an overview. Pigment cell research. vol 18. issue 1. 2005-03-30. PMID:15649148. |
additional attention will be drawn to a readily seen phenomenon in nf1: hyperpigmentation overlying (plexiform) neurofibromas, which could suggest common etiopathogenetic-environmental cues or mechanisms underlying calms and neurofibromas. |
2005-03-30 |
2023-08-12 |
Not clear |
| Christian A Merlo, Sean M Studer, John V Conte, Stephen C Yang, Joshua Sonnett, Jonathan B Oren. The course of neurofibromatosis type 1 on immunosuppression after lung transplantation: report of 2 cases. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. vol 23. issue 6. 2005-03-23. PMID:15366441. |
although an increased risk for cancer has been documented in nf1, the rapid malignant degeneration of a neurofibroma following transplantation raises concern about immunosuppression and transplantation candidacy among individuals with nf1. |
2005-03-23 |
2023-08-12 |
Not clear |
| Steven L Carroll, Mark S Stonecyphe. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. Journal of neuropathology and experimental neurology. vol 64. issue 1. 2005-03-03. PMID:15715079. |
patients with neurofibromatosis type 1 (nf1), one of the most common genetic disease affecting the nervous system, develop multiple neurofibromas that can transform into aggressive sarcomas known as malignant peripheral nerve sheath tumors (mpnsts). |
2005-03-03 |
2023-08-12 |
mouse |
| Steven L Carroll, Mark S Stonecyphe. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. Journal of neuropathology and experimental neurology. vol 64. issue 1. 2005-03-03. PMID:15715079. |
in part i of this review, we discussed findings demonstrating that a loss of nf1 tumor suppressor gene function in neoplastic schwann cells is a key early step in neurofibroma formation and that progression from neurofibroma to mpnst is associated with abnormalities of additional tumor suppressor genes, including p53, ink4a, andp27(kip1). |
2005-03-03 |
2023-08-12 |
mouse |
| George A Mashour, Pablo Hernáiz Driever, Melanie Hartmann, Stephanie N Drissel, Tingguo Zhang, Bianca Scharf, Ursula Felderhoff-Müser, Sadatoshi Sakuma, Reinhard E Friedrich, Robert L Martuza, Victor Felix Mautner, Andreas Kurt. Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clinical cancer research : an official journal of the American Association for Cancer Research. vol 10. issue 17. 2005-02-15. PMID:15355893. |
neurofibromatosis type 1 (nf1) is characterized by systemic development of neurofibromas. |
2005-02-15 |
2023-08-12 |
Not clear |
| Pascale Lévy, Ivan Bièche, Karen Leroy, Béatrice Parfait, Janine Wechsler, Ingrid Laurendeau, Pierre Wolkenstein, Michel Vidaud, Dominique Vidau. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis. Clinical cancer research : an official journal of the American Association for Cancer Research. vol 10. issue 11. 2004-12-27. PMID:15173083. |
the hallmark of nf1 is the development of heterogeneous benign neurofibromas, which may appear as dermal neurofibromas or plexiform neurofibromas. |
2004-12-27 |
2023-08-12 |
Not clear |
| Pascale Lévy, Dominique Vidaud, Karen Leroy, Ingrid Laurendeau, Janine Wechsler, Giulia Bolasco, Béatrice Parfait, Pierre Wolkenstein, Michel Vidaud, Ivan Bièch. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Molecular cancer. vol 3. 2004-12-08. PMID:15255999. |
the hallmark of nf1 is the onset of heterogeneous (dermal or plexiform) benign neurofibromas. |
2004-12-08 |
2023-08-12 |
Not clear |
| Alain Drouet, Pierre Wolkenstein, Jean-Pascal Lefaucheur, Stéphane Pinson, Patrick Combemale, Romain K Gherardi, Pierre Brugières, Jeffrey Salama, Pascal Ehre, Philippe Decq, Alain Créang. Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain : a journal of neurology. vol 127. issue Pt 9. 2004-10-15. PMID:15289270. |
neurofibromatosis 1 (nf1) is a common disease which is a source of various multisystemic manifestations related either to the accumulation of neurofibromas or to specific developmental abnormalities. |
2004-10-15 |
2023-08-12 |
Not clear |
| Alain Drouet, Pierre Wolkenstein, Jean-Pascal Lefaucheur, Stéphane Pinson, Patrick Combemale, Romain K Gherardi, Pierre Brugières, Jeffrey Salama, Pascal Ehre, Philippe Decq, Alain Créang. Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain : a journal of neurology. vol 127. issue Pt 9. 2004-10-15. PMID:15289270. |
the neurofibroma is the hallmark lesion of nf1 and develops from peripheral nerves. |
2004-10-15 |
2023-08-12 |
Not clear |
| Alain Drouet, Pierre Wolkenstein, Jean-Pascal Lefaucheur, Stéphane Pinson, Patrick Combemale, Romain K Gherardi, Pierre Brugières, Jeffrey Salama, Pascal Ehre, Philippe Decq, Alain Créang. Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain : a journal of neurology. vol 127. issue Pt 9. 2004-10-15. PMID:15289270. |
association of proximal large neurofibromas, peripheral neuropathies and subcutaneous neurofibromas may constitute a phenotype of nf1 with a severe prognosis. |
2004-10-15 |
2023-08-12 |
Not clear |
| Chana Palmer, Jacek Szudek, Harry Joe, Vincent M Riccardi, J M Friedma. Analysis of neurofibromatosis 1 (NF1) lesions by body segment. American journal of medical genetics. Part A. vol 125A. issue 2. 2004-09-28. PMID:14981716. |
café-au-lait spots and neurofibromas are defining features of neurofibromatosis 1 (nf1), but they vary greatly in number, size, and clinical importance from patient to patient. |
2004-09-28 |
2023-08-12 |
Not clear |